Skip to main content
. 2020 May;33(2):165–174. doi: 10.2337/ds19-0031

FIGURE 1.

FIGURE 1

Pathophysiology of type 2 diabetes with therapeutic targets of glucose-lowering therapies. Adapted from ref. 8 in ref. 9; reprinted with permission from refs. 8 and 9. DPP-4i, dipeptidyl peptidase 4 inhibitor; MET, metformin; TZD, thiazolidinedione.